Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Non-Current Liabilities: 2014-2025

Historic Total Non-Current Liabilities for ImmunityBio (IBRX) over the last 8 years, with Sep 2025 value amounting to $927.2 million.

  • ImmunityBio's Total Non-Current Liabilities fell 14.89% to $927.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.2 million, marking a year-over-year decrease of 14.89%. This contributed to the annual value of $844.9 million for FY2024, which is 13.04% down from last year.
  • As of Q3 2025, ImmunityBio's Total Non-Current Liabilities stood at $927.2 million, which was up 2.46% from $904.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Total Non-Current Liabilities registered a high of $1.1 billion during Q3 2024, and its lowest value of $393.9 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $930.9 million, with a median of $908.6 million in 2023.
  • Per our database at Business Quant, ImmunityBio's Total Non-Current Liabilities surged by 110.25% in 2021 and then decreased by 15.92% in 2025.
  • Over the past 5 years, ImmunityBio's Total Non-Current Liabilities (Quarterly) stood at $712.4 million in 2021, then climbed by 10.97% to $790.5 million in 2022, then climbed by 22.91% to $971.6 million in 2023, then declined by 13.04% to $844.9 million in 2024, then decreased by 14.89% to $927.2 million in 2025.
  • Its Total Non-Current Liabilities was $927.2 million in Q3 2025, compared to $904.9 million in Q2 2025 and $873.7 million in Q1 2025.